OKYO Pharma Limited(OKYO)Earnings, Financials & Key Ratios

Key Thesis Takeaways

• OKYO Pharma faces a precarious financial outlook characterized by a lack of commercial revenue and a heavy reliance on external financing to fund operations.
• The company's capital allocation appears skewed toward administrative overhead, with SG&A expenses of $2.8M in 2026Q2 significantly outpacing the $44.0K allocated to R&D.
• Investors should monitor the company's ability to secure additional funding, as the current negative equity position of $3.4M and limited cash reserves suggest a high probability of further dilutive events.